Platelet apoptosis. On the issue of factors of insufficient antiplatelet drug effectiveness
Abstract
Increased platelet aggregation is the bases for the pathogenesis of many diseases. However, it’s not always possible to overcome platelets hyperaggregation and to prevent the development of thrombotic complications using antiplatelet drugs. This article focuses on apoptosis of platelets, which are supposed to be regarded as unaccounted factor of platelets activation and as a new predictor of complications with coronary heart diseases patients, and its mechanisms – as a new target for antiplatelet drugs
Key words
References1. Shitikova AS. Platelets hemostasis. Sankt-Peterburg, 2000. 227 p. (in Russian)
2. Gresele P., Fuster V., Lopez J. et al. Platelets in hematologic and cardiovascular disorders: a clinical handbook. Cambridge: Cambridge University Press, 2008. 511 p.
3. Kroemer G., Reed J.C. Mitochondrial control of cell death // Nat. Med. 2000. 6. 513–519.
4. Danial N.N., Korsmeyer S.J. Cell death: critical control points // Cell. 2004. 116. 205–219.
5. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death // Science. 2004. 305. 626–629.
6. Jacobson M.D., Burne J.F., Raff M.C. Programmed cell death and Bcl-2 protection in the absence of a nucleus // EMBO J. 1994. 13. 1899–1910.
7. Castedo M., Hirsch T., Susin S.A. et al. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis // J. Immunol. 1996. 157. 12–21.
8. Martin S.J., Finucane D.M., Amarante-Mendes G.P. et al. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity // J. Biol. Chem. 1996. 271. 28753–28756.
9. Birka C., Lang A.P., Kempe S.D. et al. Enhanced susceptibility to erythrocyte «apoptosis» following phosphate depletion // Eur. J. Physiol. 2004. 448. 471–477.
10. Perrotta P.L., Perrotta C.L., Snyder E.L. Apoptotic activity in stored human platelets // Transfusion. 2003. 43. 526–535.
11. Rand M.L., Wang H., Bang K.W. et al. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence // J. Thromb. Haemost. 2004. 2. 651–659.
12. Leytin V., Mykhaylov S., Starkey A.F. et al. Intravenous immunoglobulin inhibits anti-GPIIb-induced platelet apoptosis in a murine model of ITP // Br. J. Haematol. 2006. 133. 78–82.
13. Kleiman N.S., Freedman J.E., Tracy P.B. et al. Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development // Plateles. 2008. 19. 239–251.
14. Vanags D.M., Orrenius S., Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis // Br. J. Haematol. 1997. 99. 824–831.
15. Shcherbina A., Remold-O’Donnell E. Role of caspase in a subset of human platelet activation responses // Blood. 1999. 93. 4222–4231.
16. Wolf B.B., Goldstein J.C., Stennicke H.R. et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation // Blood. 1999. 94. 1683–1692.
17. Li J., Xia Y., Bertino A.M. et al. The mechanism of apoptosis in human platelets during storage // Transfusion. 2000. 40. 1320–1329.
18. Bertino A.M., Qi X.Q., Li J. et al. Apoptotic markers are increased in platelets stored at 37 °C // Transfusion. 2003. 43. 857–866.
19. Leytin V., Allen D.J., Mykhaylov S. et al. Pathologic high shear stress induces apoptosis events in human platelets // Biochem. Biophys. Res. Commun. 2004. 320. 303–310.
20. Leytin V., Allen D.J., Mykhaylov S. et al. Thrombin-triggered platelet apoptosis // J. Thromb. Haemost. 2006. 4. 2656–2663.
21. Pereira J., Soto M., Palomo I. et al. Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs // Thromb. Haemost. 2002. 87. 905–909.
22. Leytin V., Mutlu A., Mykhaylov S. et al. The GPIIb/IIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187 // Haematologica. 2009. 94. 1783–1784.
23. Lin K.H., Chang H.C., Lu W.J. et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-activating agents // Platelets. 2009. 20. (8). 575–581.
24. Mann K.G., Brummel K., Butenas S. What is all that thrombin for? // J. Thromb. Haemost. 2003. 1. 1504–1514.
25. Brummel-Ziedins K.E., Pouliot R.L., Mann K. G. Thrombin generation: phenotypic quantitation // J. Thromb. Haemost. 2004. 2. 281–288.
26. Flynn A.N., Buret A.G. Proteinase-activated receptor 1 (PAR-1) and cell apoptosis // Apoptosis. 2004. 9. 729–737.
27. Zain J., Huang Y.Q., Feng X. et al. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells // Blood. 2000. 95. 3133–3138.
28. LeytinV., Allen D.J., Lyubimov E., Freedman J. Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation // Br. J. Haematol. 2007. 136. (5). 762–764.
29. Rink T.J., Sage S.O. Calcium signalling in human platelets // Annu. Rev. Physiol. 1990. 52. 431–439.
30. Rosado J.A., Sage S.O. Protein kinase C activates non-capacitative calcium entry in human platelets // J. Physiol. 2000. 529. 159–169.
31. Amor N.B., Pariente J.A., Salido G.M. et al. Thrombin-induced caspases 3 and 9 translocation to the cytoskeleton is independent of changes in cytosolic calcium in human platelets // Blood. Cell Mol. Dis. 2006. 36. 392–401.
32. Ben Amor N., Pariente J.A., Salido G.M., Bartegi A., Rosado J.A. Caspases 3 and 9 are translocated to the cytoskeleton and activated by thrombin in human platelets. Evidence for the involvement of PKC and the actin filament polymerization // Cell Signal. 2006. 18. 1252–1261.
33. Nozawa Y., Nakashima S., Nagata K. Phospholipid-mediated signaling in receptor activation of human platelets // Biochim. Biophys. Acta. 1991. 1082. 219–238.
34. Brunati A.M., Deana R., Folda A. et al. Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with the cellular migration of the protein // J. Biol. Chem. 2005. 280. 21029–21035.
35. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology // J. Thromb. Haemost. 2005. 3. 1800–14.
36. Cheung W.M., D’Andrea M.R., Andrade-Gordon P., Damiano B.P. Altered vascular injury responses in mice deficient in protease-activated receptor-1 // Arterioscler. Thromb. Vasc. Biol. 1999. 19. 3014–3024.
37. Takada M., Tanaka H., Yamada T. et al. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat // Circ. Res. 1998. 82. (9). 980–987.
38. Andrade-Gordon P., Derian C.K., Maryanoff B.E. et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats // J. Pharmacol. Exp. Ther. 2001. 298. 34–42.
39. Rosado J.A., Lуpez J.J., Gуmez-Arteta E. et al. Early caspase-3 activation independent of apoptosis is required for cellular function // J. Cell Physiol. 2006. 209. 142–152.
40. Blokhin DY. Programmed cells death: the way from induction to execution // Patogenez. 2003. (2). 25–33.
41. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis // Mol. Cell. 2002. 9. (3). 459–470.
42. Muzio M., Stockwell B.R., Stennicke H.R. et al. An induced proximity model for caspase-8 activation // J. Biol. Chem. 1998. 273. (5). 2926–2930.
43. Guyer K.E. The present state of aspirin and clopidogrel resistence // Hamostaseologie. 2009. 29. (3). 285–290.
44. Pinto Slottow T.L., Bonello L., Gavini R. et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis // Am. J. Cardiol. 2009. 104. (4). 525–530.
45. Ben-Dor I., Kleiman N.S., Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy // Am. J. Cardiol. 2009. 104. (2). 227–233.
46. Reny J.L., Bonvini R.F., Barazer I. et al. The concept of aspirin «resistance». Mechanisms and clinical relevance // Rev. Med. Inteme. 2009. 30. (12). 1020–1029.
47. Steinhubl S.R., Berger P.B., Mann J.T. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial // JAMA. 2002. 288. (19). 2411–2412.
48. Kumar A., Kao J. Platelet resistance to antiplatelet drugs // Recent Pat Cardiovasc. Drug Discov. 2009. 4. (2). 98–108.
49. Kuliczkowski W., Witkowski A., Polonski L. et al. Interindividual variability in the response to oral antiplatelet drugs. A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology // Eur. Heart J. 2009. 30. (4). 426–435.
50. Daleke D.L., Lyles J.V. Identification and purification of aminophospholipid flippases // Biochim. Biophys. Acta. 2000. 1486. 108–127.
51. Zamzami N., Kroemer G. The mitochondrion in apoptosis: how Pandora’s box opens // Nat. Rev. Mol. Cell Biol. 2001. 2. 67–71.
52. Zamzami N., Kroemer G. Methods to measure membrane potential and permeability transition in the mitochondria during apoptosis // Methods Mol. Biol. 2004. 282. 103–115.
53. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis: an update // Apoptosis. 2003. 8. 115–128.
54. Remenyi G., Szasz R., Friese P., Dale G.L. Role of mitochondrial permeability transition pore in coated-platelet formation // Arterioscler. Thromb. Vasc. Biol 2005. 25. 467–471.
55. Leytin V., Allen1 D.J., Mutlu1 A. et al. Mitochondrial control of platelet apoptosis. effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore // Lab. Invest. 2009. 89. 374–384.
56. Leung R., Gwozdz A.M., Wang H. et al. Persistence of procoagulant surface expression on activated human platelets. involvement of apoptosis and aminophospholipid translocase activity // J. Thromb. Haemost. 2007. 5. (3). 560–570.
57. Alberio L., Safa O., Clemetson K.J. et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin // Blood. 2000. 95. 1694–1702.
58. Dale G.L., Friese P., Batar P. et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface // Nature. 2002. 415. 175–179.
59. Kotovа Y.N., Kostanovа E.A., Rosenfeld M.A. et al. Effect of cysteine proteases inhibitors at platelet and plasmatic elements of hemostasis system // Biologicheskiye membrany. 2009. 26. (5). 1–7. (in Russian)
60. Kotova Y.N., Ataullakhanov F.I., Panteleev M.A. Coated platelets formation is regulated by the dense granule secretion of ADP acting via the P2Y12 receptor // J. Thromb. Haemost. 2008. 6. 1603–1605.
61. London F.S., Marcinkiewicz M., Walsh P.N. A subpopulation of platelets respon to thrombin- or SFLLRN-stimulation with binding sites for factor IXa // J. Biol. Chem. 2004. 279. (19). 19854–19859.
62. Panteleev M.A., Ananyeva N.M., Greco N. J. et al. Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex // J. Thromb. Haemost. 2005. 3. (11). 2545–53.
63. Jobe S.M., Leo L., Eastvold J.S., Dickneite G. et al. Role of FcRgamma and factor XIIIA in coated platelet formation // Blood. 2005. 106. (13). 4146–4151.
64. Remenyi G., Szasz R., Friese P., Dale G.L. Role of mitochondrial permeability transition pore in coated-platelet formation // Arterioscler. Thromb. Vasc. Biol. 2005. 25. (2). 467–471.
65. Rand J.H., Wu X., Andree H.A.M. et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a «lupus procoagulant» phenomenon // Blood. 1998. 5. 1652–1660.
66. Van Heerde W.L., De Groot P.G., Reutelingsperger C.P.M. The complexity of the phospholipid binding protein ANV // Thromb. Haemost. 1995. 73. 172–179.
67. Gerke V., Moss S.E. Annexins: from structure to function // Physiol. Rev. 2002. 82. 331–371.
68. Rand J.H. «Annexinopathies» a new class of diseases // N. Engl. J. Med. 1999. 340. 1035–1036.
69. Van Ryn McKenna J., Merk H., Muller T.H. et al. The effect of heparin and annexin V on fibrin accretion after injury in the jugular vein of rabbits // Thromb. Haemost. 1993. 69. 227–230.
70. Van Heerde W.L., Sakariassen K.S., Hemker H.C. et al. ANV inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under flow conditions // Arterioscler. Thromb. 1994. 14. 824–830.
71. Rodriguez-Garcia M.I., Fernandez J.A., Rodriguez A. et al. ANV auto antibodies in rheumatoid arthritis // Ann. Rheum. Dis. 1996. 55. (12). 895–900.
72. Kaburaki J., Kuwana M., Yamamoto M. et al. Clinical significance of anti-ANV antibodies in patients with systemic lupus erythematosus // Am. J. Hematol. 1997. 54. 209–213.
73. Reutelingsperger C.P., van Heerde W.L. ANV, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis // Cell. Mol. Life. Sci. 1997. 53. 527–532.
74. Ogawa H., Zhao D., Dlott J.S. et al. Elevated anti-ANV antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities // Am. J. Clin. Pathol. 2000. 114. 619–628.
75. Lakos G., Kiss E., Regeczy N., Tarjan P. et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases // J. Rheumatol. 2000. 27. 924–949.
76. Gaspersic N., Rot U., Cucnik S. et al. Anti-annexin V antibodies in patients with cerebrovascular disease // Ann. Rheum. Dis. 2003. 62. 188–189.
77. Nakamura N., Shidara Y., Kawaguchi N. et al. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells. involvement of ANV // Biochem. Biophys. Res. Commun. 1994. 205. 1488–1493.
78. Cederholm A., Svenungsson E., Jensen-Urstad K. et al. Decreased binding of annexin V to endothelial cells // Arterioscler. Thromb. Vasc. Biol. 2005. 25. 198-203.
79. Kaneko N., Matsuda R., Hosoda S. et al. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction // Clin. Chim. Acta. 1996. 251. 65–80.
80. Roldan V., Marнn F., Pineda J. et al. Annexin V levels in survivors of early myocardial infarction // Rev. Esp. Cardiol. 2002. 55. 1230–1234.
81. Shojaie M., Sotoodah A., Roozmeh S. et al. Annexin V and anti-annexin V antibodies: two interesting aspects in acute myocardial infarction // Thromb. J. 2009. 7. 13.
82. Vasinа LV Annexin A5 and annexin A5 antibodies in acute coronary syndrome with and without ST-elevation // Regional'noe krovoobrashcheniye i microcirculyatsiya. 2009. (2). 22–25. (in Russian)
83. Petrishchev N.N., Vasina L.V. Endogenous mechanisms which prevent endothelium apoptosis in atherosclerosis // Estestvennyye i tekhnicheskiye nauki. 2008. (4). 116–126. (in Russian)
84. Jacobson M.D., Raff M.C. Programmed cell death and Bcl-2 protection in very low oxygen // Nature. 1995. 374. 814–816.
85. Skulachev VP. In intermembrane space mitochondrion hides a "suicide protein", which induces apoptosis after coming out to the cytosol (review) // Biochemistry. 1996. 61. (11). 2060–2063. (in Russian)
86. Brune B., Sandau, K., von Kneten A. Apoptotic cells death and nitric oxide. activation mechanisms and antagonistic signaling pathways // Biochemistry. 1998. 63. (7). 966–975. (in Russian)
87. Malyshev I.Y., Manukhin E.B. Stress, adaptation and nitric oxide // Biochemistry. 1998. 63. (7). 992–1006. (in Russian)
88. Taylor B.S., Alarson L.H., Billiards T.R. Inducible nitric oxide synthase in the liver. regulation and function // Biochemistry. 1998. 63. (7). 905–923. (in Russian)
89. Rossig L., Haendeler J., Hermann C. et al. Nitric oxide down-regulates MKP-3 mRNA levels. involvement in endothelial cell protection from apoptosis // J. Biol. Chem. 2000. 275. 25502–25507.
90. Moriya R., Uehara T., Nomura Y. Mechanism of nitric oxide-induced apop-tosis in human neuroblastoma SH-SY5Y cells // FEBS Lett. 2000. 484. 253–260.
91. Borutaite V., Morkuniene R., Brown G.C. Nitric oxide donors, nitrosothiols and mitochondrial respiration inhibitors induce caspase activation by different mechanisms // FEBS Lett. 2000. 467. 155–159.
92. Hortelano S., Dallaporta B., Zamzami N. et al. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition // FEBS Lett. 1997. 410. 373–377.
93. Balakirev M.Yu., Khramtsov V.V., Zimmer G. Modulation of the mitochondrial permeability transition by nitric oxide // Eur. J. Biochem. 1997. 246. 710–718.
94. Rukoyatkina N., Walter U., Gambaryan S. NO inhibits platelet apoptosis by cGMP-dependent and-independent pathways // BMC Pharmacol. 2009. 9. (Suppl. 1). 60.
95. Wachowicz B., Rywaniak J.Z., Nowak P. Apoptotic markers in human blood platelets treated with peroxynitrite // Platelets. 2008. 19. (8). 624–635.
96. Lopez J.J., Salido G.M., Gomez-Arteta E. et al. Thrombin induces apoptotic events through the generation of reactive oxygen species in human platelets // J. Thromb. Haemost. 2007. 5. (6). 1283–1291.
97. Bjorkerud S., Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability // Am. J. Pathol. 1996. 149. (2). 367–380.
98. Hardwick S.J., Hegvi L., Clare K. et al. Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein // J. Pathol. 1996. 179. (3). 294–302.
99. Joving S., Crisby M., Thyberg J., Nilsson J. DNA fragmentation and ultrastructural changes of degenerating cells in atherosclerotic lesions and smooth muscle cells exposed to oxidized LDL in vitro // Arterioscler. Thromb. Vasc. Biol. 1997. 17. (10). 2225–2231.
100. Escargueil-Blanc I., Meilhac O., Pieraggi M.T. et al. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Prevention by aurintricarboxylic acid // Arterioscler. Thromb. Vasc. Biol. 1997. 17. (2). 331–339.
101. Papassotiropoulos A., Ludwig M., Naib-Majani W., Rao G.S. Induction of apoptosis and secondary necrosis in rat dorsal root ganglion cell cultures by oxidized low density lipoprotein // Neurosci. Lett. 1996. 209. (1). 33–36.
102. Sener A., Ozsavci D., Oba R. et al. Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia? // Clin. Biochem. 2005. 38. (12). 1081–1087.
103. Yeh J.J., Tsai S., Wu D.C. et al. P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection // Blood. 2010. 115. (21). 4247–4253.
Berezovskaya G.A. – candidate of medical sciences, senior researcher of the laboratory of acute coronary syndrome, e-mail: berezovgel@mail.ru
